|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2005-6-20
|
|
pubmed:abstractText |
Mantle cell lymphoma (MCL) has the worst prognosis of all B-cell lymphomas and has poor response to conventional therapy. It is characterized by the presence of a chromosomal translocation t(11:14) (q13;q32) which results in deregulated cyclin D1 expression. Since defects in cell cycle regulation and apoptosis are primary events in MCL, small-molecule inhibitors of cdks-cyclins may play an important role in the therapy of this disorder. CYC202 (Seliciclib, R-roscovitine; Cyclacel Ltd., Dundee, UK) is a purine analogue and a selective inhibitor of the cdk2-cyclin E as well as cdk7-cyclin H and cdk9-cyclin T.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:BertoniFF,
pubmed-author:CatapanoCC,
pubmed-author:CavalliFF,
pubmed-author:Gianella-BorradoriAA,
pubmed-author:LacrimaKK,
pubmed-author:LambertiniCC,
pubmed-author:MaccallumD EDE,
pubmed-author:RinaldiAA,
pubmed-author:TaborelliMM,
pubmed-author:ValentineMM,
pubmed-author:ZuccaEE
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1169-76
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:15851403-Antineoplastic Agents,
pubmed-meshheading:15851403-Apoptosis,
pubmed-meshheading:15851403-Blotting, Western,
pubmed-meshheading:15851403-Cell Cycle Proteins,
pubmed-meshheading:15851403-Cell Division,
pubmed-meshheading:15851403-Cell Line, Tumor,
pubmed-meshheading:15851403-Cyclin-Dependent Kinases,
pubmed-meshheading:15851403-Humans,
pubmed-meshheading:15851403-In Situ Nick-End Labeling,
pubmed-meshheading:15851403-Lymphoma, Mantle-Cell,
pubmed-meshheading:15851403-Purines,
pubmed-meshheading:15851403-Transcription Factors
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
|
|
pubmed:affiliation |
Experimental Oncology and Lymphoma Unit, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
